PRESS RELEASE

BBK Worldwide Launches TCN® Engage, a Disruptive Tech-Service Ecosystem for an Inclusive and Positive Clinical Trial Experience

Breakthrough Clinical Trial Support System Establishes a New Standard in Engagement

BBK Worldwide (BBK), the global leader in maximizing the clinical trial experience for patients and providers, today announced the launch of TCN^® Engage, a breakthrough engagement ecosystem dedicated to providing a full array of visit support services from the time a patient responds to an advertisement for a clinical trial opportunity through to their completion of the study.

Clinical trial patient recruitment saw a lot of advancements in 2022, from patient concierge programs to DEI enrollment strategies. But what’s in store for 2023? We asked six of our industry experts to weigh in with their predictions.

In the September issue of PM360, Rob Laurens joins other industry thought leaders to share their opinions on what it takes today for life sciences companies to practice a patient-first approach.

We are all hoping that 2022 will be a better year for the world, one where the impact of the pandemic truly begins to subside for everyone around the globe. That said, it is a basic truth that every challenge presents some opportunity, and the impact of COVID-19 on the clinical research and development industry has been no exception.

The One Thing Every Sponsor Needs to Start a Decentralized Clinical Trial Off Right

I recently sat down with Chief Innovation Officer Rob Laurens to discuss how BBK's Engagement Solution Center solves many of the challenges sponsors face when planning and initiating a decentralized clinical trial. 

RSG® Arrive Reaches Milestone of 20,000 Completed Trips

Enrollment, Engagement, and Satisfaction Data Confirms That Extending Study Support Beyond the Care Setting Yields Positive Results

Launched in 2012, RSG® Arrive has made clinical trial participation possible for thousands of patients worldwide. Today, the program has reached a major milestone with the completion of 20,000 trips. 

Create a Patient- and Site-Centric Environment for Decentralized Clinical Trials

Hear from the Experts! 

As decentralized clinical trials reshape the clinical research landscape, BBK Worldwide Chief Patient Officer Rob Laurens and Lead Concierge Anthony Gaudio discuss efforts to help study sponsors embrace these trials with ease and confidence.

Earlier this week, BBK Principal Rob Laurens went one-on-one with Outsourcing-Pharma discussing the launch of BBK's Engagement Solution Center for decentralized and post-marketing clinical trials, which features concierge service delivery and a robust patient experience portal to ease the clinical trial journey.

In this in-depth interview, Rob addresses the importance and advantages of centralizing design, management, operations, and communications of patient support services. In addition, he provides insight into some of the conversations that led to the creation of the center. Click here to read the full article.

BBK Worldwide Launches the Engagement Solution Center for Decentralized and Post-Marketing Clinical Trial Success

Concierge Service Delivery and Robust Patient Experience Portal Ease Clinical Trial Journey

The COVID-19 pandemic has significantly accelerated the need to reshape research and development. Most specifically, it has led to demand for increased funding for decentralized and larger randomized clinical trials to inform clinical decisions and guide future research.

By launching the Engagement Solution Center, BBK Worldwide (BBK) is making patient-centric and inclusive trials an immediate and actionable reality for study sponsors.

For part two of our Crystal Ball series, we asked a few more of our industry experts to comment on the clinical research landscape and to share their predictions for 2021.

Rob Laurens, Principal, RSG Services

Do you think a lot of the travel services rapidly deployed in response to COVID-19 will remain in effect? Will they become part of the standard offering?

Undoubtedly, many of the extraordinary support services deployed as a means to directly respond to the impact of the COVID-19 pandemic on clinical trial participant travel not only will remain available after the distribution and anticipated positive impact of vaccines, but also will be enhanced to serve the needs of a redefined approach and capabilities for clinical trial conduct by sponsors and CROs.